Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553848 | 0.93 | ALDH1A1 (0.60) | ALDH1A1LMNAGRM2L3MBTL1F2RL3 | |
| SCHEMBL1909166 | 0.89 | GRM2 (0.53) | ALDH1A1LMNAGRM2HSD17B10 | |
| SCHEMBL553854 | 0.88 | HSD17B10 (0.60) | ALDH1A1LMNAGRM2L3MBTL1F2RL3 | |
| SCHEMBL2821953 | 0.88 | LMNA (0.54) | ALDH1A1LMNAGRM2SMN1; SMN2CYP19A1 | |
| SCHEMBL28595790 | 0.88 | ESR1 (0.55) | ALDH1A1LMNAGRM2SMN1; SMN2TSHR | |
| SCHEMBL30739109 | 0.87 | GRM2 (0.49) | ALDH1A1LMNAGRM2L3MBTL1F2RL3 | |
| SCHEMBL3092869 | 0.87 | HSD17B10 (0.51) | ALDH1A1LMNAGRM2L3MBTL1SMN1; SMN2 | |
| SCHEMBL554548 | 0.87 | GRM2 (0.51) | ALDH1A1LMNAGRM2SMN1; SMN2HSD17B10 | |
| SCHEMBL553801 | 0.87 | GRM2 (0.53) | ALDH1A1LMNAGRM2L3MBTL1F2RL3 | |
| SCHEMBL16246754 | 0.87 | KLKB1 (0.57) | ALDH1A1LMNAGRM2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | ALDH1A1 461/4885LMNA 1512/4885GRM2 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.